CTMX CYTOMX THERAPEUTICS INC Investments/Divestments 8-K Filing 2023 - Transition Agreement with AbbVie CytomX Therapeutics regains exclusive rights to develop CX-2029 through a Transition Agreement with AbbVie, with royalty obligations and potential future milestones to be paid to Seattle Genetics.Get access to all SEC 8-K filings of the CYTOMX THERAPEUTICS INC